SARASOTA, FL--(MARKET WIRE)--Jul 20, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that sterility tests of specific cell lines for producing PT-401, the lead drug in the Company's product pipeline, have been completed satisfactorily, a significant step in developing material for preclinical and clinical trials. Studies performed by BioReliance®-Invitrogen Bioservices consisted of tests for the presence of bacterial and fungal contaminants, tests for bacteriostatic and fungistatic activity, tests for the presence of Mycoplasma and tests for the detection of MMV (murine minute virus). All of the tests were successful and no contamination was reported.
